

Research & Reviews: Research Journal of Biology

Bone Marrow Transplantation: A Review

Kamini J*

Department of Biotechnology, Graphic Era Deemed University, Dehradun, Uttarakhand, India

Review Article

Received: 26/07/2016
Accepted: 19/08/2016
Published: 23/08/2016

*For Correspondence

Kamini Joshi, Department of
Biotechnology, Graphic Era
Deemed University, Dehradun,
Uttarakhand, India
Tel: 8958179346; E-mail:
kaminijoshi13@gmail.com

Keywords: Bone marrow,
Hematopoietic tissue, Niemann
pick disease, Myelodysplasia,
Myeloma, Graft failure.

ABSTRACT

Bone marrow transplantation refers to the technical application of basic medicine principles for the treatment of a range of growth and allied disorders that originate within the bone marrow. The results have improved throughout the past fifteen years, being the most practiced for the treatment of the acute and chronic leukemia. Autologous bone marrow transplantation has given a wide opportunity for the treatment of leukemia and solid tumours that is awaiting the perfection of techniques for the effective removal of residual growth cells likewise as more practical medical aid. The employment of this method at its gift stage of development for the treatment of benign medical disorders that cause severe morbidity (i.e., thalassemia or RBC anaemia), is disputed, raises serious moral problems, and can't be suggested habitually at this point. Complications of bone marrow transplantation like graft rejection, graft-versus-host illness, and opportunist infections are mentioned.

INTRODUCTION

Bone marrow

Bone marrow can be defined as the spongy tissue present inside the bone that is responsible for hematopoiesis. In humans, red blood cells are unit made by cores of bone marrow within the heads of long bones in an exceedingly method called sanguification [1]. On average, bone marrow constitutes four of the whole body mass of humans; in AN adult having 65 kg of mass (143 lbs.), bone marrow usually accounts for about a pair of 2.6 kg (5.7 lb). The hematopoietic element of bone marrow in a day produces just about 500 billion blood cells that use the vasculature of bone marrow as a way to the body's circulation. Bone marrow is additionally a key element of the systema lymphaticum, manufacturing the lymphocytes that support the body's system [1-3].

Types of bone marrow

Bone marrow can be of two varieties, red or yellow, diaphysial portion marking on whether or not it consists in the main hematopoietic tissue (red-colored) or fatty tissue (yellow colored). Every type of bone marrow is particularly tube-shaped structured, being enriched with various blood vessels and capillaries [4].

Bone marrow initially seems in close to the top of fetus life and becomes active about three weeks later. Bone marrow supersedes the liver because it is the major hematopoietic organ at 32-36 weeks'

gestation. At the time of birth bone marrow is red. With age it starts appearing yellow in color. In associate degree adult, roughly 1/2 the bone marrow remains red.

Red bone marrow can be found in flat bones, hip bone, or (breast) bone, skull, ribs, vertebrae, and shoulder blades, additionally as within the metaphyseal and epiphysial ends of the long bones, upper side of the tibia, thighbone and arm bone, and can be found wherever spongy bone is present [3].

Yellow marrow is found within the diaphysial portion's hollow interior or inside the shaft of long bones. By the time an individual reaches maturity, nearly all of the red bone marrow is replaced by marrow. However, the marrow will revert to red if there's exaggerated demand for red somatic cells; rise in instances of blood loss. As, the stem cells differentiate to become a selected equitably cell—a white somatic cell, red blood cell, or thrombocyte [5-9]. Normally, mature cells are discharged from the marrow into the blood.

Bone marrow transplant

Bone marrow transplant replaces bone marrow that's either not operating properly or has been ablated by therapy or radiation. Doctors believe that for several cancers, the donor's white blood cells might attack any remaining cancer cells, like once white cells attack bacterium or viruses once fighting associate degree infection [10,11].

Bone marrow transplant can be used in following condition:-

- Certain cancers, like leukemia, Myelodysplasia, lymphoma and myeloma.
- The disease that is responsible for destruction of bone marrow cell, like aplastic anemia, inherent leukopenia, severe system sicknesses, RBC anemia, and hypochromic anemia.
- Bone marrow destruction due to chemotherapy [12].

Stem cells from blood and bone marrow donation area unit are used to treat some cancers, such as leukemia, myeloma, and alternative diseases [13]. Artificially or biologically processed stem cells from a donor is taken and if they are histocompatible to the patient then those are infused into another person or into a similar person at a later time. These infused cells can then travel the bone marrow and initiate corpuscle production [14-16].

In severe cases of sickness of the bone marrow, first the bone marrow cells area unit 1 is killed off with medicine or irradiation, then the new stem cells area unit introduced.

In some extremely severe cancer patient, before the administration of radiation or therapy, a number of the patient's processed stem cells are collected and once the medical care is finished later infused back to the patient, to revive the system [17].

Niemann Pick disease includes series of genetic autosomal disorders; these are caused by a chain of mutations of the gene called sphingomyelin phosphodiesterase-1 gene (SMPD1) that encodes the acid sphingomyelinase (ASM), involved in the degradation of sphingomyelin. The acid sphingomyelinase

results in the accumulation of sphingomyelin in the cells of the bone marrow liver, lungs, spleen and in the brain of some patients [18,19]. Niemann Pick type A is a severe neurodegenerative deformity that has no enzymatic activity. It occurs or develops in infancy with abdominal enlargement due to hepatosplenomegaly, cherry red macula and feeding difficulties [20-22]. Moreover, it is accompanied with progressive loss of acquired motor skills. In the central nervous system (CNS), the increased accumulation of sphingomyelin leads to neurologic disturbances and Intellectual disability generally resulting in death by 3 years of age.

Niemann decide blood group could be a slow paced illness with an equivalent cistron defect however it's a lot of residual catalyst activity. The illness develops in pre-teen years with the spleen's and Liver development; although the central nervous system (CNS) isn't concerned in adulthood pulmonic difficulties and ataxy area unit the key complications [22-25].

Traumatic medulla spinalis injury leads to immediate impairments below the amount of injury caused by the loss of neural cells and axons. This primary injury is followed by secondary pathophysiological cascade that causes progressive tissue loss for weeks to months when the slur, resulting in the formation of fluid-filled cysts encircled by connective tissue. The endogenous response among the lacerate medulla spinalis fails to reorganize medulla spinalis tissue in an exceedingly manner that results in useful repair [26]. Presently no treatments exist which will effectively restore lost motor, sensory and autonomous operate when medulla spinalis injury.

Mesenchymal stem cells (MSCs) derived largely from bone marrow, however conjointly from animal tissue and canal, area unit being studied as a possible repair strategy for medulla spinalis injury [27,28]. Typically, MSCs will be simply isolated, polite and ready for transplantation into a medulla spinalis lesion. MSCs secrete varied molecules that area unit acknowledged to exert paracrine effects leading to repair [29]. When medulla spinalis injury, MSCs have the potential to decrease secondary tissue loss when medulla spinalis injury and this neuroprotective impact has been shown to be related to with moderate useful enhancements. MSCs secrete neurotrophic factors, resembling brain-derived neurotrophic issue, glialderived protein and nerve protein that have the potential to decrease vegetative cell necrobiosis and/or promote nerve fiber regeneration. Additionally, MSCs secrete factors that have proliferative and helpful effects on blood vessels, as well as vascular epithelium protein and angiopoietin-1, severally. However, survival of MSCs within the lacerate medulla spinalis is poor, limiting the provision of those organic process factors to the close animal tissue and therefore their effects that cause repair. As a result of it's been shown that improved survival of MSCs is related to improve anatomical and/or useful repair, it's vital to grasp mechanisms of transplanted death and to develop ways to enhance Master of Science survival. This review provides an outline of studies that have investigated Master of Science survival within the lacerate medulla spinalis and summarizes current Master of Science survival promoting ways specifically that specialize in bone marrow derived MSCs [30-33].

COLLECTION OF BONE MARROW

For bone marrow transplant the stem cells are collected by many ways

Apheresis

For this procedure, blood is drawn from the arm of patient. After that, patient's blood and stem cells are separated by a machine in which blood is taken from one end and stem cells are separated and the rest of the blood is again pushed pumped back to patients body [30,34].

From pelvis

From a donor's pelvis Stem cells can be directly collected. This process is not widely used as you need an expert and you need to have a local anesthesia. To do this technique, we need to have a hollow needle that will be pierced inside the body/bone again and again to suck out stem cells [35-38].

Umbilical cord or Placenta can be used to collect stem cells after a baby is born. Stored at a cord blood bank in -76°C for future utilization [36].

A close match will scale back the chance that recipient's system can attack the donor cells and in depth match additionally reduces the chance that cells from the donor's marrow or blood can attack recipients body [37].

If stem cells are induced from another person, the doctors can wish to search out a donor whose stem cells match recipient's stem cell as closely as attainable [38-40]. A close match will scale back the chance that recipient's system can attack the donor cells. A detailed match additionally reduces the chance that cells from the donor's marrow or blood can attack recipient's body [41].

HLA TISSUE TYPING

People having somatic cell transplants are matched with donors through a procedure known as HLA diagnostic test. HLAs (Human leukocyte antigen proteins) found on the white blood cells surface. Immune system differentiates between self and foreign cell on the basis of this antigen protein [42,43].

An identical twin can be considered as best donor as we know as HLA proteins are inherited. We can consider siblings as a match. However, many do not have a decent match in their families [44].

If there is no matching donor present in the family, then the search widens to incorporate folks outside the family [40,45]. Doctors can look for:

- Donors who are not a family member but a perfect match
- HLA mismatches in the family
- Unrelated donors who are perfect HLA mismatch
- Patient's Umbilical cord blood that can be consider as a perfect match

People who offer their own stem cells for later use do not have to undergo HLA matching

Medical tests and exams for compatibility

- Blood Tests
- Chest X Ray and Lung Function Tests
- Dental Exam

- Computed Tomography Scan, Skeletal X Ray, or Bone Scan
- Heart Tests
- Bone Marrow Biopsy (Bone marrow biopsy can be defined as complete removal of cells from the bone) [46-50].

PROCEDURE

A bone marrow diagnostic test could also be carried out in hospitals or in the health care provider's workplace. The sample for bone marrow biopsy can be collected from breast or girdle bone. Other areas are also used to collect sample [51-55].

The marrow is extracted in following manner:

- Recipient may be given medication to make him relax, if needed.
- Desensitizing medication is injected into the skin and surface of the bone after the health care provider cleans off the skin [54,56].
- A diagnostic test needle is inserted into the bone. The middle of the needle is removed and a hollow needle gets penetrated deeper into the bone. This captures a small sample, or core, of bone marrow at in the needle [57-62].
- Then the needle and sample is removed.
- Pressure and so a bandage square measure applied to the skin.

A bone marrow aspiration may additionally be done, typically before the diagnostic test is taken [63]. Once the skin is numbed, the needle is inserted into the bone, and a syringe is employed to withdraw the liquid bone marrow [64-66]. If this is often done, the needle is going to be removed and repositioned. Or, another needle could also be used for the diagnostic test [67-70].

Abnormal results can also appear because of cancers of the bone marrow [71] (leukemia, lymphoma, myeloma, or different cancers). The results might find the reason for anaemia (very less red blood cells number), abnormal white blood cells, or thrombocytopenia (very less platelets number) [72,75].

Additional conditions that the check could also be performed:

- Disseminated mycosis (a body-wide fungous infection)
- Hairy cell leukemia
- Hodgkin or non-Hodgkin malignant neoplastic disease
- Idiopathic aplastic anemia
- Multiple malignant neoplasm
- Myelodysplastic syndrome (MDS)
- Neuroblastoma
- Polycythemia Vera

- Primary amyloid
- Primary fibrosis
- Primary thrombocythemia
- Secondary aplastic anemia
- Secondary general amyloid
- Waldenstrom macroglobulinemia

LIMITATIONS

Infections

Infections can occur eventually if recipient's system is weak. The chance of infections decreases as recipient's system recovers [76,77].

Steps can be taken to forestall infections, such as:

- Bathing or showering daily
- Carefully cleansing teeth and gums
- Cleaning the surroundings wherever central line enters the body
- Foods which have harmful bacteria should be avoided, significant of raw fruits and vegetables [78,79].

Transplant recipients generally an area unit are given vaccines to forestall viruses and infections, reminiscent of the grippe (influenza) and respiratory illness. If patient has developed associate degree infection, doctor can prescribe medication to treat it [80-83].

Graft-versus-host disease

GVHD may be a common complication for people that get stem cells from a donor. In GVHD, the new stem cells attack recipient's body [84]. Acute GVHD happens among ninety to a hundred days of the transplant. Chronic GVHD begins over ninety to a hundred days once the transplant or goes on the far side ninety days once the transplant. GVHD are often minor or life threatening [85].

Symptoms occur like

- A rash that starts on the soles of feet and palms of recipient's hands and spreads to mid-section. Over time, the rash could cowl the entire body. Skin will blister or peel if the rash is incredibly unhealthy.

- Nausea (feeling sick to stomach), vomiting, loss of appetite, abdomen cramps, and symptom. Doctors verify however unhealthy GVHD relies on the severity of symptom.
- Jaundice and abdomen pain, symptoms indicate liver harm.

Acute GVHD is treated with glucocorticoids, similar to alkyl group Liquid Pred, Liquid Pred together with cyclosporine, antithymocyte simple protein, or being antibodies [80,86]. Chronic GVHD is treated with steroids— mostly cyclosporine and Liquid Pred on alternating days [87,88].

Older individuals, people that have had acute GVHD before, and other people United Nations agency receive stem cells from mismatched or unrelated donor square measure at hyperbolic risk for GVHD [89-93].

Doctors will scale back probabilities of obtaining GVHD by:

- Closely matching recipient stem cells to donor's through HLA diagnostic test.
- Using medicines to suppress body system.
- Removing some varieties of T cells from donor cells. In GVHD, T cells attack the body [94,95].
- Using blood of Umbilical cord because the supply of donor cells.

Graft failure

Graft failure happens if recipient's system rejects the new stem cells. It can also occur if not enough stem cells area unit used, the new stem cells area unit broken throughout storage, or recipient's bone marrow is broken when the transplant[94,96].

Graft failure is additional doubtless to occur in those that receive less preparation for his or her transplants. Those that get stem cells from poorly matched donors are additional doubtless to possess graft failure [96,97].

Other complication

The therapy and/or radiation recipient receive throughout transplant preparation will cause complications. Generally these complications occur long once the transplant is done [98]. Complications will embrace sterility, cataracts, new cancers, and harm to the liver, kidneys, lungs, or heart [99].

Cancer relapse

In some those that get somatic cell transplants to treat cancer such as leukemia, it might be possible that the cancer eventually comes back. It happens in a lot of typically in those that use their own stem cells for the transplant (autologous transplant) than from those who take stem cells from other source (an allogenic transplant) [99].

This distinction happens as results of stem cells received from another person acknowledge new cancer cells as foreign and destroy them. This can be referred to as the graft-versus-tumor result. Somebody's own stem cells do not acknowledge the new cancer cells as foreign. This enables the cancer cells to grow and multiply [98,100].

Doctors use therapy to assist stop or treat the return of cancer in those that have had somatic cell transplants. This treatment stimulates the system to attack cancer cell

CONCLUSION

From this review article on which the author has done the research it has been concluded that bone marrow transplantation in this era has meant a lot to the recent science. The article confirms that the recent studies on this transplantation have been a boon in the life of a human being.

If we scroll in our past studies related to stem cell and bone marrow we can research that there was almost no scope of this boon and patient due to several diseases died too. In such cases these studies have become a gift in the scientific society. If we see the statistics then we came to know that more than 1000 people have been gifted with this transplantation with a minor costing and major profit.

As this is understood that some people are not very lucky to have a successful bone marrow transplant due to graft rejection and other complications. But this doesn't mean that it's not suitable; as every coin has two faces same is for this there is a light side and a dark side. In coming years this research can lead to new inventions as sky is the limit for any research.

REFERENCES

1. Sánchez-Robles MJ et al. Collection, Isolation and Proliferation of Bone Marrow Cells of Rat. J Biotechnol Biomater. 2015;5:189.
2. Somia HA et al. Evaluation of Bone Marrow Derived Mesenchymal Stem Cell Potency on Wound Healing. J Stem Cell Res Ther. 2015;5:312.
3. Othman A and Hassan M. Mesenchymal Stem Cells as a Potential Source of Hepatocyte like Cells. J Bone Marrow Res. 2016;4:166.
4. Suva LJ et al. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7:208-218.
5. Zmouli N et al. Thrombopathies and Allogeneic Bone Marrow Transplantation: Stakes and Perspectives. J Bone Marrow Res. 2015;3:161.
6. Gu D et al. Prognostic Significance of Preoperative Thrombocytosis in Patients with Endometrial Carcinoma: Our Experience and Review of the Literature. Gynecol Oncol Trends. 2015;1:101.
7. Tawa MG et al. CD45 (-) Acute Lymphoblastic Leukemia Characterized by Migratory Arthritis, Thrombocytosis, Thrombosis and Early Relapse: Case Report and Literature Review. J Blood Disord Transfus. 2012;3:114.

8. <http://humangenetics.conferenceseries.com/pdfs/stemcell-2016-stem-cell-research-2016-conference-finale-program.pdf>.
9. Mansouritorghabeh H and Ghasemi A. The Current Role of Bone Marrow Transplantation in the Treatment of Hemophilia A. *J Hematol Thrombo Dis*. 2014;2:143.
10. Ikehara S. Rationale for Bone Marrow Transplantation in Treatment of Various Intractable Diseases. *Immunome Res*. 2015;11:091.
11. Pant-Purohit M et al. Tumor Marker Rise during Second Course of High-Dose Chemotherapy in Cancer: Outcome Analysis. *J Bone Marrow Res*. 2013;1:118.
12. Mc Donald LT and LaRue AC. Bone Marrow Stem Cell Contribution to Pulmonary Homeostasis and Disease. *J Bone Marrow Res*. 2015;3:162.
13. Andolina A. Bone Marrow Transplantation and Mesenchymal Stem Cells in Niemann Pick A Disease. *J Bone Marrow Res*. 2015;3:155.
14. Ebihara Y et al. Unusual Extramedullary Relapse after Haploidentical Bone Marrow Transplantation in a Patient with Acute Lymphoblastic Leukemia. *J Blood Disord Transfus*. 2014;4:155.
15. Oudega M and Ritfeld G. Bone Marrow-derived Mesenchymal Stem Cell Transplant Survival in the Injured Rodent Spinal Cord. *J Bone Marrow Res*. 2014;2:146.
16. Oyama N. Dynamic Action of Myofibroblasts in Skin and Bone Marrow Transplantation. *J Bone Marrow Res*. 2014;2:143.
17. Kiang JG and Gorbunov NV. Bone Marrow Mesenchymal Stem Cells Increase Survival after Ionizing Irradiation Combined with Wound Trauma: Characterization and Therapy. *J Cell Sci Ther*. 2014;5:190.
18. Andolina A. Bone Marrow Transplantation and Mesenchymal Stem Cells in Niemann Pick A Disease. *J Bone Marrow Res*. 2015;3:155.
19. Deng YB et al. Modified Bone Marrow Stromal Cells Therapy for Central Nervous System Disorders. *Adv Genet Eng*. 2014;3:e111.
20. Brown A, et al. Central Nervous System Vasculitis Complicating Rheumatoid Arthritis in a Patient on a TNF Inhibitor: a Causal Association? Case Report and Systematic Review. *J Vasc*. 2016;2:104.
21. Fischer M, et al. Intravascular Large B-Cell Lymphoma Mimicking Central Nervous System Vasculitis. *J Clin Case Rep*. 2016;6:767.
22. Abbas Jaffri S and Ahsan T. Frequency of Hyponatremia in Central Nervous System Infections. *J Neuroinfect Dis*. 2015;6:179.
23. Uyanıkgil Y et al. Effects of Pineal Gland Neurohormone Melatonin on Cancer Cells in the Human Central Nervous System. *Cancer Med Anticancer Drug*. 2016;1:e102.
24. Janet MR and Linda SP. Compressive Sensing: Real-time Data Acquisition and Analysis for Biosensors and Biomedical Instrumentation. *Biosens J*. 2015;4:2.

25. Rogers E and Hamm C. Primary melanoma of the central nervous system: A case report and review of the literature. International Conference & Exhibition on Cancer Science & Therapy, Las Vegas, USA. 2011.
26. Aydin HE et al. Use of Dural Graft to Prevent Cerebrospinal Fluid (CSF) Leakage and its Effects on Medulla Spinalis: An Experimental Study. *J Neurol Disord.* 2015;3:202.
27. Fazaeli H et al. Introducing of a New Experimental Method in Semen Preparation: Supernatant Product of Adipose Tissue: Derived Mesenchymal Stem Cells (SPAS). The Patient's Perspective. *JFIV Reprod Med Genet.* 2016;4:178.
28. Ghodsizad A et al. Biological Similarities Between Mesenchymal Stem Cells (Mscs) and Fibroblasts. *J Cytol Histol.* 2010;1:101.
29. Khoshchehreh R, et al. Rat Pancreatic Stromal Cells (PSC) affect Differentiation of Human Mesenchymal Stem Cells (hMSC) into Insulin-Producing Cells (IPCs) In vitro. *J Cell Sci Ther.* 2012;3:130.
30. Baoxia C. Angiopoietin-1, Angiopoietin-2 and Myocardial Ischemia-Reperfusion Injury. *J Hypertens.* 2012;1:e107.
31. Moustafa MNK, et al. Morphological and Morphometric Study of the Development of Seminiferous Epithelium of Donkey (*Equus asinus*) from Birth to Maturity. *J Cytol Histol.* 2015;6:370.
32. Carle MV et al. Tears of the Retinal Pigment Epithelium during Aflibercept Therapy: PED and Treatment Characteristics. *J Clin Exp Ophthalmol.* 2014;5:373.
33. Iwashita M, et al. Effect of Eyewash Solution (Commercial Washing Solution) on the Corneal Epithelium: Adverse Effects of Benzalkonium Chloride on the Eye Surface. *J Clin Exp Ophthalmol.* 2016;7:571.
34. Hao Y et al. miR-146a is upregulated during Retinal Pigment Epithelium (RPE)/Choroid Aging in Mice and Represses IL-6 and VEGF-A Expression in RPE Cells. *J Clin Exp Ophthalmol.* 2016;7:562.
35. Chang YJ et al. Autophagic Regulation of Retinal Pigment Epithelium Homeostasis. *Pigmentary Disorders.* 2015;2:227.
36. Colón E et al. Autocrine/Paracrine Insulin-like Growth Factor Binding Protein-3 Acts as Pro-apoptotic Factor for Leydig cells in the Rat Testis. *J Steroids Horm Sci.* 2016;7:174.
37. Mia MM and Bank RA. Paracrine Factors of Human Amniotic Fluid-Derived Mesenchymal Stem Cells Show Strong Anti-Fibrotic Properties by Inhibiting Myofibroblast Differentiation and Collagen Synthesis. *J Stem Cell Res Ther.* 2016;5:282.
38. Incorvaia C et al. Pathophysiological Mechanisms Underlying the Efficacy and Safety of Sublingual Immunotherapy. *J Allergy Ther.* 2016;7:e113.
39. Ahmad R et al. Peroxynitrite Modified Photoadducts as Possible Pathophysiological Biomarkers: A Short Review. *J Mol Biomark Diagn.* 2015;6:263.

40. Tilman V. Pulmonary Edema: A Unifying Pathophysiological Formula. *J Cardiovasc Dis Diagn.* 2015;3:194.
41. Fatima L and Fatah C. Pathophysiological and Pharmacological Effects of Snake Venom Components: Molecular Targets. *J Clin Toxicol.* 2014;4:190.
42. Cheepsattayakorn A and Cheepsattayakorn R. Tuberculosis in Association with Human Leukocyte Antigen. *J Mycobac Dis.* 2014;4:161.
43. Mishra MN and Dudeja P. Human Leukocyte Antigens and Host Factors are Associated with Good Health in Ageing Indian Population. *Hereditary Genet.* 2014;3:128.
44. Alhilali HA et al. Human Leukocyte Antigen-G and Certain Auto-antibodies Profile in Inflammatory Bowel Disease Patients. *J Clin Cell Immunol.* 2014;5:183.
45. Saraswat A et al. Immuno-Informatic Speculation and Computational Modeling of Novel MHC-II Human Leukocyte Antigenic Alleles to Elicit Vaccine for Ebola Virus. *J Vaccines Vaccin.* 2012;3:141.
46. Niparuck P et al. The Effect of Mycophenolate Mofetil on Graft Versus Host Disease in Cyclosporine Induced Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. *J Bone Marrow Res.* 2016;4:165.
47. Khallaf FG and Kehinde EO. The Effect of Serum from Acute Traumatic Brain or Spinal Cord Injury Patients on the Growth of Human Bone Marrow- Derived Mesenchymal Stem Cells. *J Trauma Treat.* 2016;5:299.
48. Keromnes N et al. FDG PET/CT for Initial Staging of Diffuse Large B-Cell Lymphoma: Is Diffuse Bone Marrow Uptake a Reflection of Disease Involvement?. *J Bone Marrow Res.* 2016;4:164.
49. Ipek Y et al. Defibrotide for Prevention and Treatment of Venous Occlusive Disease in Adults: Single-Center Experience. *J Bone Marrow Res.* 2014;2:148.
50. M Bouche and L Madaro. Invited Commentary on "Enrichment and Characterization of Two Subgroups of Committed Osteogenic Cells in the Mouse Endosteal Bone Marrow with Expression Levels of CD24". *J Bone Marrow Res.* 2014;2:145.
51. Leotta S et al. Autologous Transplantation in 1st Cr Aml Patients with Purged or Unpurged Bone Marrow: Good Clinical Results in Favorable Cytogenetic Group and in those Infused with a Low Number of Marrow Cells. *J Bone Marrow Res.* 2014;2:138.
52. Palaniyandi S et al. Beneficiary Effect of Autologous Hematopoietic Cell Transplantation in Idiopathic Ulcerative Dermatitis C57BL/6 Mice. *J Bone Marrow Res.* 2014;2:139.
53. Verma K. Bone Marrow in the Realm of Measurable Science. *J Bone Marrow Res.* 2013;1:120.
54. Gupta BM and Bala A. Bone Marrow Research in India: A Scientometric Study, 2003-12. *J Bone Marrow Res.* 2013;1:108.
55. Singh R et al. The Contribution of Hematopoietic Stem / Progenitor Cell and Bone Marrow Stroma Cell Cd44v6 and Cd44v7 to Hematopoiesis. *J Stem Cell Res Ther.* 2015;5:295.

56. Soler Rich R et al. Treatment of Knee Osteoarthritis with Autologous Expanded Bone Marrow Mesenchymal Stem Cells: 50 Cases Clinical and MRI Results at One Year Follow-Up. *J Stem Cell Res Ther.* 2015;5:285.
57. Bolander J et al. The Effect of Activating FGFR3 Mutations on Osteogenic Differentiation and Ectopic Bone Formation. *J Tissue Sci Eng.* 2012;S2:003.
58. Yu F et al. Ultrasound-mediated Microbubble Destruction Promotes Bone Marrow Mesenchymal Stem Cell Transplantation for Myocardial Infarction Therapy. *J Clin Exp Cardiol.* 2014;5:333.
59. Mansouritorghabeh H and Ghasemi A. The Current Role of Bone Marrow Transplantation in the Treatment of Hemophilia A. *J Hematol Thrombo Dis.* 2014;2:143.
60. Matte U et al. Bone Marrow-Derived Mononuclear Cells Differentiate into Hepatocyte- Like Cells within Few Hrs without Fusion. *J Cell Sci Ther.* 2014;5:163.
61. Li M et al. Update on Bone Marrow Collection and Stem Cell Transplantation. *J Stem Cell Res Ther.* 2014;4:156.
62. Greco OT et al. Cardiomyopathy and Cell Therapy: Ejection Fraction Improvement and Cardiac Muscle Mass Increasing, after a Year of Bone Marrow Stem Cells Transplantation, by Magnetic Resonance Image. *J Stem Cell Res Ther.* 2013;S6:008.
63. Sharma A et al. Intrathecal Autologous Bone Marrow Mononuclear Cell Transplantation in a Case of Adult Autism. *Autism.* 2013;3:113.
64. Khoj L et al. A Case of Dengue Fever-Induced Severe Aplastic Anemia Salvaged by Allogeneic Bone Marrow Transplant. *J Leuk (Los Angel).* 2013;1:120
65. Hendarto H et al. The Effect of Bone Marrow Transplantation on Oocyte-Granulosa Cell Interaction and Follicular Development of Cisplatin-Induced Ovarian Failure in Rat. *J Stem Cell Res Ther.* 2013;3:133.
66. Charfi R et al. PRES Induced By Cyclosporin with Normal Blood Concentrations in a Bone Marrow Recipient. *J Drug Metab Toxicol.* 2015;6:178.
67. Roodman GD. Mechanisms of bone metastasis. *N Engl J Med.* 2014;350:1655-1664.
68. Yin T and Li L. The stem cell niches in bone. *J Clin Invest.* 2006;116:1195-1201.
69. Khallaf FG and Kehinde EO. The Effect of Serum from Acute Traumatic Brain or Spinal Cord Injury Patients on the Growth of Human Bone Marrow- Derived Mesenchymal Stem Cells. *J Trauma Treat.* 2016;5:299.
70. Tahani AM et al Therapeutic Effects of Bone Marrow Stem Cells in Diabetic Rats. *J Comput Sci Syst Biol.* 2016;9:58-68.
71. Keromnes N et al. FDG PET/CT for Initial Staging of Diffuse Large B-Cell Lymphoma: Is Diffuse Bone Marrow Uptake a Reflection of Disease Involvement?. *J Bone Marrow Res.* 2016;4:164.
72. Harif M. Hairy Cell Leukemia Associated with a Bone Marrow Tuberculosis. *J Cytol Histol.* 2015;7:382.

73. Mikhailov VM et al. Bone Marrow Cells Influences for Function of Rat Decidua. *J Cell Sci Ther.* 2015;6:224.
74. Ismail AE et al. Role of Autologous Bone Marrow Stem Cell Transplantation in the Treatment of Active Ulcerative Colitis. *J Stem Cell Res Ther.* 2015;5:313.
75. Jiang H et al. Bone Marrow Transplantation Followed by Growth Factors Injection in a Patient with Femoral Neck Nonunion: A Case Report. *J Trauma Treat.* 2015;S2:012.
76. Omics Conferences (2016) The role of the bone marrow examination in the diagnosis of hematological malignancies in limited resource centre. *Cancer Diagnostics Conference & Expo, Rome, Italy.*
77. Omics Conferences (2016) Recommendations for collecting and processing good quality bone marrow specimens. *5th International Conference on Pathology, Chicago IL, USA.*
78. Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. *Hematol ASH Educ Program.* 2011;231-237.
79. Mizuta S et al. Pre-transplant administration of imatinib for allogeneic hematopoietic stem cell transplantation in patients with BCR-ABL-positive acute lymphoblastic leukemia. *Blood.* 2014;123:2325-2332.
80. Zhang FH et al. The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Hematology.* 2013;18:151-157
81. Tanguy Schmidt A et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. *Biol Blood Marrow Transplant.* 2013;19:150-155.
82. Biondi A et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. *Lancet Oncol.* 2012;13:936-945.
83. Yanada M et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. *J Clin Oncol.* 2006;24:460-466.
84. Schultz KR et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. *J Clin Oncol.* 2009;27:5175-5181.
85. Yanada M et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. *Br J Haematol.* 2008;143:503-510.
86. Ravandi F et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. *Blood.* 2013;122:1214-1221.

87. Hoelzer D. Monitoring and managing minimal residual disease in acute lymphoblastic leukemia. *Am Soc Clin Oncol Educ Book*. 2013;290-293.
88. Jeha S et al. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. *Cancer*. 2014;120:1514-1519.
89. Lee S et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. *Leukemia*. 2012;26:2367-2374.
90. Nishiwaki S et al. Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. *Anticancer Res*. 2010;30:2415-2418.
91. Bachanova V et al. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. *Leukemia*. 2014;28:658-665.
92. Ribera JM et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. *Haematologica*. 2010;95:87-95.
93. Burke MJ et al. Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. *Bone Marrow Transplant*. 2009;43:107-113.
94. Caocci G et al. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. *Biol Blood Marrow Transplant*. 2012;18:652-654.
95. Watanabe A et al. Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Pediatr Int*. 2013;55:e56-e58.
96. Pfeifer H et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. *Leukemia*. 2013;27:1254-1262.
97. Mizuta S et al. Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. *Blood Cancer J*. 2012;2:e72.
98. Fujisawa S et al. Imatinib-based chemotherapy for newly diagnosed BCR-ABL positive acute lymphoblastic leukemia: Japan Adult Leukemia Study Group (JALSG) Ph+ALL208 Study. *Blood*. 2014;124:932.
99. Przepiorka D et al. 1994 Consensus conference on acute GVHD grading. *Bone Marrow Transplant*. 1995;15:825-828.
100. Sullivan KM et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. *Blood*. 1981;57:267-276.

